44 2033180199
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Journal of Clinical Genetics and Genomics

Sign up for email alert when new content gets added: Sign up

Pentaisomaltose- a promising new cryoprotectant

International Conference on STEM CELLS AND REGENERATIVE MEDICINE

November 06-07, 2019 | Tokyo, Japan

Jesper Dyrendom Svalgaard

University of Copenhagen, Denmark

ScientificTracks Abstracts: J Clin Gen Genomics

Abstract :

Cell and tissue therapy for medical and scientific use has during the past decades expanded extensively and hold promises for being an important platform for future treatment modalities. A major feature and pre-requisite for several cell products, both autologous and allogeneic off-the shelf, is the possibility of safe and efficient cryopreservation during production/treatment.

Successful cryopreservation requires effective cryoprotectants (CPAs). Classical and CPAs like glycerol and especially dimethyl sulfoxide (DMSO) have been widely used. However, the well-established side-effects and undesirable cellular effects of e.g. DMSO, has led to an increasing demand from health care professionals, patients and authorities for a reduction in the concentration of CPAs like DMSO and/or the development of safe and effective alternatives. Most development in the past decades has focused on optimizing freeze media, by combining existing CPAs and optimizing the carrier media, but new alternative CPAs have not been introduced.

Pentaisomaltose, a low-molecular-weight carbohydrate, is a new and promising CPA. Our work during the past years has proven that pentaisomaltose can replace DMSO for cryopreservation of hematopoietic stem cells and, also to significantly reduce the required concentration of DMSO needed for successful cryopreservation of other cell types (ASC, T-Cells). Pentaisomaltose, thus, could prove a promising new addition to the CPA repertoire, solving some of the problems faced by the field today.

Biography :

Jesper Dyrendom Svalgaard is MSc, PhD and research fellow in the stem cell facility, at the Department of Clinical Immunology, Rigshospitalet, University of Copenhagen. In his research Jesper D Svalgaard is focusing on the development and testing of alternative cryoprotectants for cryopreservation of hematopoietic stem cells products and other cell types. Lately, part of his research interests has been testing how to reduce the DMSO concentration in mesenchymal stem cells and T cells.

E-mail: Jesper.Dyrendom.Svalgaard@regionh.dk

 
Google Scholar citation report
Citations : 24

Journal of Clinical Genetics and Genomics received 24 citations as per Google Scholar report

pulsus-health-tech
Top